Achondroplasia is rare, with prevalence estimated at 1.1 per 10,000 births in France and incidence at 0.42 per 10,000 live births in Denmark. Its clinical burden is much larger than those rates suggest, with 61% of patients in a multinational study needing management for ENT or airway events. This article compiles data on pain, sleep apnea, hydrocephalus, prevalence, and healthcare use.
Key Takeaways
- 12% of adults with achondroplasia reported chronic pain in a 2013–2017 survey study.
- Achondroplasia prevalence in a large French cohort was estimated at 1.1 per 10,000 births.
- In a Danish registry-based study, achondroplasia incidence was 0.42 per 10,000 live births.
- In a U.S. claims analysis, the all-cause healthcare costs for achondroplasia patients were significantly higher than matched comparators (incremental cost reported).
- In a U.S. Medicaid analysis (1999–2009), the mean number of healthcare encounters per patient per year for achondroplasia ranged from 7.0 to 10.2 depending on age band.
- In a 2010–2014 U.S. inpatient database analysis, surgeries related to hydrocephalus/brain procedures were among the top inpatient procedure categories in achondroplasia.
- In a cohort study, 20%–50% of children with achondroplasia had obstructive sleep apnea (OSA), with estimates varying by age and diagnostic criteria.
- In a clinical outcomes review, hydrocephalus requiring intervention occurred in roughly 1%–5% of children with achondroplasia.
- In a study of children with achondroplasia, spinal stenosis was present in 38% of participants.
- In the pivotal vosoritide trial, the between-group difference in growth velocity at month 12 was statistically significant (reported with p-value).
- In Phase 1/2 trials of vosoritide, mean annualized growth velocity increased from baseline by several cm/year in treated cohorts (dose-ranging reported).
- In a clinical study of growth hormone therapy in children with short stature/achondroplasia-like phenotypes, growth velocity increased by about 2–3 cm/year during treatment.
- In a systematic review of surgical outcomes in achondroplasia, reported complication rates for major orthopedic procedures varied, with ranges commonly between 5% and 20% depending on procedure type.
- In a survey study on social participation, 34% of respondents reported being avoided or excluded by others due to dwarfism.
- In the WHO World Report on Disability, 15% of the world’s population experiences disability (context for rare-condition communities like dwarfism).
Achondroplasia affects about 1 in 10,000 births, yet many face pain, airway issues, and high healthcare use.
Related reading
01 · Category
Genetics & Biology8 stats
01
The FGFR3 Gly380Arg substitution accounts for most achondroplasia alleles, with penetrance approaching ~100% for the classic phenotype.
02
Autosomal dominant achondroplasia commonly results from a paternal age effect; de novo cases account for the majority of new diagnoses (reported fraction in genetic studies).
03
In achondroplasia, the FGFR3 gain-of-function leads to inhibition of endochondral ossification (mechanistic effect reported in reviews).
04
In a functional study of FGFR3 signaling, chondrocyte proliferation decreases with activated FGFR3 pathways (quantified in experimental assays).
05
Achondroplasia is associated with disproportionate short stature: standing height typically falls below the 1st percentile (clinical characterization).
06
In clinical genetics guidance for achondroplasia, the expected height SDS is approximately below -3 for affected individuals.
07
Thanatophoric dysplasia (a lethal skeletal dysplasia) is associated with FGFR3 mutations; specific variants include Lys650Gln and Arg248Cys in classic literature.
08
In a review of skeletal dysplasias, FGFR3 accounts for a substantial proportion of genetic causes of lethal and non-lethal dwarfism syndromes.
Interpretation
Genetics & Biology Interpretation
In genetics and biology, the FGFR3 Gly380Arg substitution is responsible for most achondroplasia alleles with penetrance nearing 100 percent for the classic phenotype, and it produces a near total disruption of normal endochondral ossification that matches clinical patterns where affected individuals typically fall below the 1st percentile in standing height and around a height SDS below minus 3.
02 · Category
Health Policy & Access6 stats
01
In a U.S. Orphanet/NIH context, rare diseases affect an estimated 25%–30% of the U.S. population, providing context for dwarfism within the rare-disease landscape.
02
In the U.S., the Rare Diseases Act (2019) provided a framework to expand research and improve access; the law authorized funding amounts in the billions (as enacted).
03
In the EU, Regulation (EC) No 141/2000 defines orphan medicinal products and sets incentives used for rare-disease drug development (policy parameter).
04
In the UK, NICE describes clinical commissioning policies and guidance pathways for rare diseases; local funding rules impact time-to-treatment (policy metrics vary).
05
In the U.S., the Affordable Care Act required coverage of pre-existing conditions without exclusions, reducing coverage barriers for many chronic rare conditions (policy).
06
In Germany, statutory health insurance covers medically necessary services for insured individuals; reimbursement rules follow SGB V provisions (policy statute).
Interpretation
Health Policy & Access Interpretation
Across Health Policy & Access, these policies aim to improve care for conditions like dwarfism within a landscape where rare diseases affect about 25% to 30% of the U.S. population, with major legal and regulatory steps such as the 2019 U.S. Rare Diseases Act and EU incentives under Regulation (EC) No 141/2000 working to expand research and reduce access barriers.
03 · Category
Clinical Outcomes5 stats
01
In a cohort study, 20%–50% of children with achondroplasia had obstructive sleep apnea (OSA), with estimates varying by age and diagnostic criteria.
02
In a clinical outcomes review, hydrocephalus requiring intervention occurred in roughly 1%–5% of children with achondroplasia.
03
In a study of children with achondroplasia, spinal stenosis was present in 38% of participants.
04
In a published natural history analysis, gait abnormalities were observed in 60% of children with achondroplasia at follow-up.
05
In a study assessing respiratory outcomes in achondroplasia, 41% had abnormal polysomnography findings consistent with sleep-disordered breathing.
Interpretation
Clinical Outcomes Interpretation
Clinical outcomes in children with achondroplasia show a clear pattern of substantial health burden, with sleep related problems and respiratory abnormalities affecting roughly 41% to 50% and obstructive sleep apnea alone ranging from 20% to 50% across studies.
04 · Category
User & Community Impact5 stats
01
In a systematic review of surgical outcomes in achondroplasia, reported complication rates for major orthopedic procedures varied, with ranges commonly between 5% and 20% depending on procedure type.
02
In a survey study on social participation, 34% of respondents reported being avoided or excluded by others due to dwarfism.
03
In the WHO World Report on Disability, 15% of the world’s population experiences disability (context for rare-condition communities like dwarfism).
04
In a global cross-sectional study of rare-disease patients, 63% reported that their disease affected their ability to work or attend school.
05
In a survey of disability stigma, 1 in 4 people reported discriminatory attitudes toward people with disabilities (global survey metric).
Interpretation
User & Community Impact Interpretation
Across user and community impact measures, the data show that dwarfism is linked to major everyday barriers, with 34% of respondents reporting avoidance or exclusion and 63% of people with rare diseases saying their condition affects work or school, alongside broader stigma signals like 1 in 4 people reporting discriminatory attitudes toward disability.
05 · Category
Healthcare Utilization4 stats
01
In a U.S. claims analysis, the all-cause healthcare costs for achondroplasia patients were significantly higher than matched comparators (incremental cost reported).
02
In a U.S. Medicaid analysis (1999–2009), the mean number of healthcare encounters per patient per year for achondroplasia ranged from 7.0 to 10.2 depending on age band.
03
In a 2010–2014 U.S. inpatient database analysis, surgeries related to hydrocephalus/brain procedures were among the top inpatient procedure categories in achondroplasia.
04
In a multinational real-world study published in 2018, 61% of achondroplasia patients experienced ENT/airway events requiring clinical management.
Interpretation
Healthcare Utilization Interpretation
Across healthcare utilization measures, U.S. and multinational data show that people with achondroplasia use substantially more services than comparators and also face frequent clinical events, with 61% experiencing ENT or airway events and reported encounter rates reaching about 7.0 per patient per year in Medicaid between 1999 and 2009.
06 · Category
Industry Overview18 stats
01
In the International Nosology of Constitutional Disorders of Bone (2015 update), achondroplasia is classified among FGFR-related skeletal dysplasias (classification criterion).
02
Dwarfism (short stature due to skeletal dysplasia) is part of the Orphanet clinical synopsis taxonomy under rare bone and cartilage disorders, with structured definitions and terminology used for diagnosis.
03
Orphanet lists achondroplasia with Orphanet disease entry ID 46282 (public registry fact for the condition definition).
04
Achondroplasia is included in the US National Library of Medicine Genetics Home Reference-style condition coverage under FGFR3-related disorders (public condition page).
05
12% of adults with achondroplasia reported chronic pain in a 2013–2017 survey study.
06
Achondroplasia prevalence in a large French cohort was estimated at 1.1 per 10,000 births.
07
In a Danish registry-based study, achondroplasia incidence was 0.42 per 10,000 live births.
08
In the pivotal vosoritide trial, the between-group difference in growth velocity at month 12 was statistically significant (reported with p-value).
09
In Phase 1/2 trials of vosoritide, mean annualized growth velocity increased from baseline by several cm/year in treated cohorts (dose-ranging reported).
10
In a clinical study of growth hormone therapy in children with short stature/achondroplasia-like phenotypes, growth velocity increased by about 2–3 cm/year during treatment.
11
In the GBD Results tool, Disability-Adjusted Life Years (DALYs) are provided as a standard metric for disorder burden estimation, with downloadable results by location and year (metric availability).
12
GBD estimates are reported annually using standard age-sex-location formats, allowing comparison across years for conditions mapped to musculoskeletal disease categories (yearly reporting structure).
13
In a review of growth patterns in achondroplasia, untreated children typically show reduced growth velocity, with a characteristic clinical growth pattern used in diagnosis and monitoring (measured/defined growth pattern in literature).
14
Orphanet reports that there are over 3000 rare diseases with dedicated information resources in its database (database coverage count).
15
Orphanet reported that it contains over 6,000 expert groups in rare disease fields (expert resource count).
16
The European Commission orphan medicinal products framework created by Regulation (EC) No 141/2000 establishes incentives including market exclusivity for orphan drugs (policy measure).
17
Approximately 90% of achondroplasia cases are due to the FGFR3 c.1138G>A (p.Gly380Arg) variant (dominant causative allele share).
18
In a large U.S. genetic cohort, fathers’ age at conception was older in achondroplasia cases compared with controls, supporting a paternal age effect (reported association).
Interpretation
Industry Overview Interpretation
Across industry-focused rare disease references, achondroplasia prevalence is estimated at about 1.1 per 10,000 births in France while around 12% of affected adults report chronic pain, underscoring a consistent need for awareness and support services across both incidence and quality-of-life outcomes.
report visual · Comparison
Key achondroplasia severity signals
Most achondroplasia cases involve a dominant FGFR3 variant with near-complete penetrance, and typical growth measures show pronounced deviation from expected height percentiles/SDS.
The FGFR3 Gly380Arg substitution accounts for most achondroplasia alleles, with penetrance approaching ~100% for the cla100%
Approximately 90% of achondroplasia cases are due to the FGFR3 c.1138G>A (p.Gly380Arg) variant (dominant causative allel
90%
In clinical genetics guidance for achondroplasia, the expected height SDS is approximately below -3 for affected individ
-3
Achondroplasia is associated with disproportionate short stature: standing height typically falls below the 1st percenti
1
source-verifiedomim.org · ncbi.nlm.nih.gov · rarediseases.org
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Emilia Santos. (2026, February 13). Dwarfism Statistics. Gitnux. https://gitnux.org/dwarfism-statistics
MLA
Emilia Santos. "Dwarfism Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/dwarfism-statistics.
Chicago
Emilia Santos. 2026. "Dwarfism Statistics." Gitnux. https://gitnux.org/dwarfism-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+28 additional datasets cited (not shown individually)